Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Andrzej Rostek/iStock via Getty Images
Scholar Rock Holding (SRRK) surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal muscular atrophy.
Isembyld, also known as apitegromab-mstn, was approved for adults and children ages 2 and older who are
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.